Peter Ulrichts

Peter Ulrichts

Company: Argenx

Job title: Scientific Lead Neuromuscular Franchise

Seminars:

Live Q&A 4:50 pm

Read more

day: Day One

Phase 3 Myasthenia Gravis Study of the FcRn Antagonist Efgartigimod 4:00 pm

• Brief overview of Myasthenia Gravis and diving into the novel mode of action of efgartigimod • Evaluating Phase 3 ADAPT trial design and redosing strategy based on patient symptoms, an individualized treatment approach • Assessing the safety and efficacy of efgartigimod in patients including secondary endpoints and prespecified analysesRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.